The economic impact of neovascular age-related macular degeneration (AMD), diabetic retinopathy (DR) and diabetic macular edema (DME): a systematic literature review of the emerging literature

Willmington, Claire; Murphy,  Aileen; Kirby, Ann

The economic impact of neovascular age-related macular degeneration (AMD), diabetic retinopathy (DR) and diabetic macular edema (DME): a systematic literature review of the emerging literature

Files

Poster_ISPOR_1124_Claire Willmington.pdf(613.1 KB)

Published Version

Date

2024

Authors

Willmington, Claire

Murphy, Aileen

Kirby, Ann

Abstract

Neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), as well as its consequence, such as diabetic macular edema (DME), are some of the leading causes of vision impairment in people aged 50 years and older. In the advanced stages of these conditions, treatment often relies on repeated intravitreal injections of anti-vascular endothelial growth factors (VEGFs), namely, ranibizumab, aflibercept faricimab, brolucizumab, and bevacizumab (off-label use). While the advent of VEGF injections changed the treatment landscape, Clinical trials investigating the therapeutic potential of gene therapy in nAMD, DR and DME show promising results and may inform future care provision. Given the high price of innovative medicines, it is essential to consider the economic costs associated with these conditions to inform resource allocation decisions.

Keywords

Neovascular age-related macular degeneration (AMD) , Diabetic retinopathy (DR) , Diabetic macular edema (DME)

Citation

Willmington, C., Murphy, A. and Kirby, A. (2024) 'The economic impact of neovascular age-related macular degeneration (AMD), diabetic retinopathy (DR) and diabetic macular edema (DME): a systematic literature review of the emerging literature', ISPOR, Barcelona, Spain, 19th November.